Neurones S.A. (0GX2.L)

Neurones S.A. (0GX2.L) — VMCI valuation read

Composite valuation read on 0GX2.L: VMCI 64/100 against a Technology sector median of 50. The 14-point above-median print is the headline number for Neurones S.A., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for 0GX2.L: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on 0GX2.L: 0GX2.L trades at 25.0x earnings, 39% above the Technology median of 18.0x; ROIC of 13.0% sits 3.0pp above the Technology median (10.0%); net debt to EBITDA of -0.3x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Technology closes the value frame.

0GX2.L rose 1.0% over the trailing 7 days, with a -4.6% read on a 30-day basis.